Quick Takeaways
- Johnson & Johnson’s Imaavy shows sustained benefits in myasthenia gravis patients over 2 years, enabling many to reduce corticosteroid use.
- Kyverna’s CAR T therapy mivocabtagene autoleucel (miv-cel) demonstrates strong, durable improvements in myasthenia gravis, potentially setting a new efficacy standard and leading to FDA approval.
- Capricor’s deramiocel may slow the functional decline in Duchenne muscular dystrophy; FDA review expected in August after additional positive trial data.
- Praxis’ ulixacaltamide for essential tremor shows significant, lasting improvements and could gain FDA approval by January 2027, unlocking a $3B+ market opportunity.
Promising Treatments for Myasthenia Gravis
Recent developments at the American Academy of Neurology meeting highlight new hope for people with myasthenia gravis. Johnson & Johnson’s drug Imaavy has shown it can maintain symptom relief for up to two years. This drug helps reduce disease severity and allows many patients to lower their corticosteroid doses. Meanwhile, a different approach using CAR T cells has shown remarkable results. The therapy from Kyverna set a new standard by providing significant improvements and possibly reducing or stopping other medications. These advances could mean better quality of life for patients and make managing the illness less burdensome in daily life.
Advances in Cell Therapy for Duchenne Muscular Dystrophy
Capricor Therapeutics is seeking approval for its cell therapy, deramiocel, to treat Duchenne muscular dystrophy. Data from ongoing trials indicate it slows the decline in muscle function, which is crucial for these patients. In early results, patients experienced a 54% slowing of upper limb deterioration and an 83% slowdown in overall functional decline. While the FDA initially rejected the therapy, Capricor has strengthened its case with additional data. If approved, this treatment could improve daily functioning and independence for many living with this challenging disease.
New Options for Essential Tremor
Praxis Medicines is making strides with its drug ulixacaltamide, designed to treat essential tremor. The recent trial results show the medication significantly improves daily activities and maintains its effects over time. Importantly, a study on whether patients can stay on the drug suggests more than half remain responsive after four weeks. Experts believe FDA approval could come as early as January 2027. If approved, ulixacaltamide could become a valuable option, offering relief to millions affected by a condition that can interfere with everyday tasks and quality of life.
Continue Your Tech Journey
Dive deeper into the world of Space and its vast mysteries.
Explore groundbreaking research and scientific advancements at the National Science Foundation (NSF).
Sci-BioV1
